Europese Unie - Nederlands - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immunologicals voor canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccins - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 en 5. 1 in product information document). het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccins - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

elanco gmbh - recombinant puk-spdv-poly2#1 dna-plasmide coderend voor salmonid alphavirus subtype 3 proteÏnen - oplossing voor injectie - recombinant puk-spdv-poly2#1 dna-plasmide coderend voor salmonid alphavirus subtype 3 proteÏnen 102 - 188 µg/ml, - other immunologicals - vissen

Europese Unie - Nederlands - EMA (European Medicines Agency)

ceva santé animale - genetisch gemodificeerde recombinant shiga-toxine-2e antigeen - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - varkens - actieve immunisatie van biggen vanaf de leeftijd van vier dagen, om de mortaliteit en klinische symptomen van oedeemziekte veroorzaakt door shiga-toxine 2e geproduceerd door escherichia coli (stec) te verminderen. begin immuniteit: 21 dagen na vaccinatie. duur van immuniteit: 105 dagen na vaccinatie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

intervet international b.v. - celgebonden levend recombinant kalkoenherpesvirus (stam hvt / ilt-138), dat de glycoproteïnen gd en gi van infectieus laryngotracheïtisvirus tot expressie brengt - immunologicals voor aves, levende virale vaccins - kip - voor actieve immunisatie van kuikens van één dag om mortaliteit, klinische symptomen en laesies als gevolg van infectie met aviaire infectieuze laryngotracheïtis (ilt) -virus en het marek-virus (md) -virus te verminderen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - feline leukemie virus recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - actieve immunisatie van katten van 8 weken of ouder tegen feliene leukemie voor de preventie van persistente viremie en klinische symptomen van de gerelateerde ziekte. het begin van de immuniteit is aangetoond 2 weken na de primaire vaccinatiekuur. de immuniteitsduur is één jaar na de laatste vaccinatie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.